Summary

at UCLA
study started
estimated completion:
Ronald Mitsuyasu (ucla)

Description

Summary

Long term safety follow-up of Cal-1 recipients

Official Title

Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct

Details

Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced with LVsh5/C46 (Cal-1), a Dual Anti-HIV Gene Transfer Construct

Keywords

HIV-1 Infection Receipt of Cal-1 Modified Hematopoietic Cellular Products Blood tests

Eligibility

You can join if…

  • Signed informed consent
  • Previous treatment with the Cal-1 modified hematopoietic cellular products

You CAN'T join if...

  • Inability to understand and provide informed consent

Locations

  • UCLA CARE Center
    Los Angeles California 90035 United States
  • Quest Clinical Research
    San Francisco California 94115 United States

Lead Scientist

  • Ronald Mitsuyasu (ucla)
    Professor, Medicine. Authored (or co-authored) 72 research publications

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Calimmune, Inc.
ID
NCT02390297
Study Type
Observational
Last Updated